IRAK1 (P51617) variants and mutations
IRAK1 (also known as P51617) is a human protein-coding gene encoding an interleukin-1 receptor-associated kinase 1 protein. It relays signals from Toll-like and IL-1 family receptors to NF-kappaB and MAPK pathways, helping initiate innate inflammatory responses. Dysregulated activation contributes to autoimmunity and some cancers, and the kinase is under investigation as a therapeutic target. This analysis covers 840 IRAK1 variants and mutations. Of these, 81% have computational variant effect predictions. Disease context includes myelofibrosis, primary myelofibrosis, and systemic lupus erythematosus. Example IRAK1 variants include A2S, P5R, and P5T.
Variant analysis overview
- Gene: IRAK1
- Protein: P51617
- UniProt accession: P51617
- Organism: Homo sapiens
- Variants analyzed: 840
- Variant scope: all variants
- Completed: 2026-08-20
Variant and mutation evidence
- Variant composition: 527 unspecified-consequence records; 87 synonymous variants; 188 missense variants; 17 frameshift variants; 9 stop-gained variants; 5 stop lost; 1 stop retained variant; 2 in-frame deletions; 2 splice-region variants; 2 substitution
- Prediction scores: 677 variants have prediction scores (81% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: myelofibrosis, primary myelofibrosis, systemic lupus erythematosus, neoplasm, neurodegenerative disease, acquired polycythemia vera, plasma cell myeloma, autoimmune disorder of central nervous system, rheumatoid arthritis, Rett syndrome, ACPA-positive rheumatoid arthritis, autoimmune disease.
Protein structure and variant hotspots
- Protein features: 2 domains; 4 binding sites; 7 post-translational modification sites.
- Structural context: 282 variants have structural context.
- PTM context: 5 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable IRAK1 variants
Examples include A2S, P5R, P5T, P7L, P7S, G8E, E9A, E9G. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- A2S (p.Ala2Ser), Ensembl rs2148644097, REVEL 0.29, CADD 23.10
- P5R (p.Pro5Arg), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- P5T (p.Pro5Thr), gnomAD rs1557131078, REVEL 0.06, CADD 21.70
- P7L (p.Pro7Leu), cosmic curated COSV57652, gnomAD rs1557131072, REVEL 0.18, CADD 24.60
- P7S (p.Pro7Ser), ExAC rs782555901, gnomAD rs782555901, REVEL 0.11, CADD 22.60
- G8E (p.Gly8Glu), TOPMed rs2065769991, REVEL 0.16, CADD 23.80
- E9A (p.Glu9Ala), rs2065769801, ClinGen CA415156729, ClinVar RCV004096619, AlphaMissense 0.11, MetaLR 0.07, Uncertain significance, not specified
- E9G (p.Glu9Gly), Ensembl rs2065769801, REVEL 0.10, AlphaMissense 0.11
- E9K (p.Glu9Lys), cosmic curated COSV10514, TOPMed rs1306839426, gnomAD rs1306839426, REVEL 0.04, CADD 17.90
- E9Q (p.Glu9Gln), TOPMed rs1306839426, gnomAD rs1306839426
- P10H (p.Pro10His), TOPMed rs1352642683, gnomAD rs1352642683, REVEL 0.10, CADD 22.80
- P10S (p.Pro10Ser), Ensembl rs2065769760, REVEL 0.02, CADD 15.40
- A11T (p.Ala11Thr), Ensembl rs2065769637, REVEL 0.06, CADD 17.40
- A12G (p.Ala12Gly), ExAC rs781859481, TOPMed rs781859481, gnomAD rs781859481
- A12V (p.Ala12Val), ExAC rs781859481, TOPMed rs781859481, gnomAD rs781859481, REVEL 0.08, CADD 15.40
- P13R (p.Pro13Arg), TOPMed rs1286251470, gnomAD rs1286251470, REVEL 0.08, CADD 23.30
- G14C (p.Gly14Cys), NCI-TCGA Cosmic COSV1003, cosmic curated COSV10031, REVEL 0.19, CADD 26.20, Variant assessed as somatic; moderate impact.
- G14S (p.Gly14Ser), TOPMed rs2065769359, REVEL 0.08, CADD 23.50
- A15G (p.Ala15Gly), ExAC rs781966404, gnomAD rs781966404, REVEL 0.09, CADD 20.30
- A15P (p.Ala15Pro), ExAC rs782079065, gnomAD rs782079065, REVEL 0.17, CADD 24.50
- Q16K (p.Gln16Lys), Ensembl rs868965434, REVEL 0.10, CADD 23.30
- H17N (p.His17Asn), gnomAD rs1557131014, REVEL 0.08, CADD 22.70
- H17Q (p.His17Gln), ExAC rs782705096, TOPMed rs782705096, gnomAD rs782705096, REVEL 0.07, CADD 18.40
- H17R (p.His17Arg), TOPMed rs2065769089, REVEL 0.03, CADD 17.20
- E21* (p.Glu21Ter), Ensembl rs868908770, CADD 34.00
- P23S (p.Pro23Ser), gnomAD rs1557130995, REVEL 0.29, CADD 23.20
- W25C (p.Trp25Cys), gnomAD rs1557130990, REVEL 0.29, CADD 23.40
- M27I (p.Met27Ile), gnomAD rs1557130980, REVEL 0.23, CADD 24.90
- M27V (p.Met27Val), Ensembl rs868986504, REVEL 0.22, CADD 24.60
- L37Q (p.Leu37Gln), Ensembl rs1603305109
- A40T (p.Ala40Thr), gnomAD rs1557130970, REVEL 0.05, CADD 19.50
- D41Y (p.Asp41Tyr), gnomAD rs1557130963, REVEL 0.80, CADD 25.90
- A46S (p.Ala46Ser), Ensembl rs868929395, REVEL 0.47, CADD 34.00
- A47D (p.Ala47Asp), Ensembl rs2065767007
- A47S (p.Ala47Ser), TOPMed rs1342744049, gnomAD rs1342744049, REVEL 0.23, CADD 17.30
- R51C (p.Arg51Cys), NCI-TCGA TCGA novel, REVEL 0.45, CADD 27.70, Variant assessed as somatic; moderate impact.
- Q53E (p.Gln53Glu), Ensembl rs1603305064
- Q53P (p.Gln53Pro), Ensembl rs2065766818
- T54S (p.Thr54Ser), cosmic curated COSV10459, NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- E55D (p.Glu55Asp), TOPMed rs2065766789, REVEL 0.24, CADD 23.20
- G63R (p.Gly63Arg), TOPMed rs1557130889, gnomAD rs1557130889, REVEL 0.27, CADD 19.90
- Q64L (p.Gln64Leu), ExAC rs781819951, TOPMed rs781819951, gnomAD rs781819951
- Q64R (p.Gln64Arg), ExAC rs781819951, TOPMed rs781819951, gnomAD rs781819951, REVEL 0.12, CADD 23.00
- R65C (p.Arg65Cys), cosmic curated COSV10588, Ensembl rs2065766605, REVEL 0.74, CADD 31.00
- R65P (p.Arg65Pro), Ensembl rs2065766566
- I74V (p.Ile74Val), cosmic curated COSV57656, TOPMed rs1257648342, gnomAD rs1257648342, REVEL 0.09, CADD 21.10
- R76G (p.Arg76Gly), Ensembl rs1603305052
- A78D (p.Ala78Asp), Ensembl rs1603305048, REVEL 0.67, CADD 26.90
- A78G (p.Ala78Gly), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- A78S (p.Ala78Ser), Ensembl rs2148643695, REVEL 0.45, CADD 25.50
- R79S (p.Arg79Ser), NCI-TCGA TCGA novel, REVEL 0.33, CADD 24.20, Variant assessed as somatic; moderate impact.
- A81G (p.Ala81Gly), TOPMed rs2065766299
- T88K (p.Thr88Lys), NCI-TCGA TCGA novel, REVEL 0.48, CADD 23.90, Variant assessed as somatic; moderate impact.
- L93P (p.Leu93Pro), gnomAD X-154012659-A-G, CADD 0.60, SIFT 0.27
- R94C (p.Arg94Cys), cosmic curated COSV57653, TOPMed rs1557130848, gnomAD rs1557130848, REVEL 0.79, CADD 27.70
- R94H (p.Arg94His), NCI-TCGA Cosmic COSV5765, cosmic curated COSV57657, REVEL 0.67, CADD 25.10, Variant assessed as somatic; moderate impact.
- R94S (p.Arg94Ser), TOPMed rs1557130848, gnomAD rs1557130848, REVEL 0.74, CADD 25.60
- A95V (p.Ala95Val), NCI-TCGA TCGA novel, REVEL 0.41, CADD 25.10, Variant assessed as somatic; moderate impact.
- R96H (p.Arg96His), rs781873339, gnomAD X-154012647-C-T, CADD 0.21, SIFT 0.45
- R96L (p.Arg96Leu), rs782684300, gnomAD X-154012650-C-A, CADD 0.52, SIFT 0.56
- D97G (p.Asp97Gly), NCI-TCGA Cosmic COSV5765, cosmic curated COSV57653, Variant assessed as somatic; moderate impact.
- W102C (p.Trp102Cys), NCI-TCGA TCGA novel, REVEL 0.26, CADD 22.50, Variant assessed as somatic; moderate impact.
- H103R (p.His103Arg), rs1236849589, gnomAD X-154012653-T-C, CADD 1.51, SIFT 0.67
- H103L (p.His103Leu), rs902013124, gnomAD X-154012656-T-A, CADD 0.47, SIFT 0.22
- P104L (p.Pro104Leu), Ensembl rs1557130761, REVEL 0.09, CADD 22.00
- P105L (p.Pro105Leu), gnomAD rs1557130759
- A106S (p.Ala106Ser), TOPMed rs2065764533, gnomAD rs2065764533, REVEL 0.04, CADD 6.07
- A106T (p.Ala106Thr), TOPMed rs2065764533, gnomAD rs2065764533, REVEL 0.13, CADD 9.81
- P107L (p.Pro107Leu), TOPMed rs1018128764, gnomAD rs1018128764, REVEL 0.09, CADD 17.10
- L108R (p.Leu108Arg), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- L108* (p.Leu108Ter), rs1557127824, gnomAD X-154012629-A-T, CADD 2.30
- P109S (p.Pro109Ser), rs200423500, ClinGen CA10558359, NCI-TCGA Cosmic COSV5765, cosmic curated COSV57655, REVEL 0.12, CADD 8.59, Uncertain significance, not specified
- P109T (p.Pro109Thr), 1000Genomes rs200423500, ExAC rs200423500, TOPMed rs200423500, gnomAD rs200423500, REVEL 0.12, CADD 8.02, Uncertain significance
- S110P (p.Ser110Pro), cosmic curated COSV10031, TOPMed rs2065764377
- S110T (p.Ser110Thr), TOPMed rs2065764377
- S110L (p.Ser110Leu), rs192972585, gnomAD X-154012626-G-A, CADD 9.33, SIFT 0.07
- P111Q (p.Pro111Gln), TOPMed rs1271670612
- P111S (p.Pro111Ser), NCI-TCGA Cosmic COSV5765, cosmic curated COSV57655, Variant assessed as somatic; moderate impact.
- P111T (p.Pro111Thr), Ensembl rs2148643509
- G112S (p.Gly112Ser), TOPMed rs2065764315, REVEL 0.06, CADD 8.67, Likely benign, not specified
- G112E (p.Gly112Glu), rs370244044, gnomAD X-154012572-C-T, CADD 5.10, SIFT 0.01
- T113I (p.Thr113Ile), rs11465829, ClinGen CA10558358, ClinVar RCV003957143, 1000Genomes rs11465829, CADD 9.38, Benign, IRAK1-related disorder
- T114M (p.Thr114Met), gnomAD X-154012581-G-A, CADD 0.55, SIFT 0.34
- A115V (p.Ala115Val), TOPMed rs1190833980, REVEL 0.04, CADD 10.30
- P116L (p.Pro116Leu), ExAC rs782115156, gnomAD rs782115156, REVEL 0.04, CADD 12.90
- P116R (p.Pro116Arg), ExAC rs782115156, gnomAD rs782115156, REVEL 0.11, CADD 17.60
- R117K (p.Arg117Lys), gnomAD rs1557130725, REVEL 0.04, CADD 5.15
- R117S (p.Arg117Ser), TOPMed rs2065764077
- R117H (p.Arg117His), rs782484829, gnomAD X-154012635-C-T, CADD 2.84, SIFT 0.61
- S120C (p.Ser120Cys), ExAC rs782002126, TOPMed rs782002126, gnomAD rs782002126, CADD 8.87, Uncertain significance, not specified
- S120F (p.Ser120Phe), rs2065707427, gnomAD X-154012599-G-A, CADD 9.48, SIFT 0.05
- I121L (p.Ile121Leu), rs201911518, ClinGen CA10558355, cosmic curated COSV57656, ClinVar RCV000968501, REVEL 0.07, CADD 9.40, Benign, not provided
- I121V (p.Ile121Val), 1000Genomes rs201911518, ESP rs201911518, ExAC rs201911518, TOPMed rs201911518, REVEL 0.08, CADD 7.07, Conflicting interpretations, not specified; not provided
- P124L (p.Pro124Leu), ExAC rs782096938, TOPMed rs782096938, gnomAD rs782096938, CADD 6.40
- A125S (p.Ala125Ser), ExAC rs781919207, TOPMed rs781919207, gnomAD rs781919207, REVEL 0.09, CADD 0.26, Uncertain significance
- A125T (p.Ala125Thr), ExAC rs781919207, TOPMed rs781919207, gnomAD rs781919207, REVEL 0.08, CADD 3.44, Uncertain significance, not specified
- E126D (p.Glu126Asp), NCI-TCGA Cosmic COSV1003, cosmic curated COSV10031, Variant assessed as somatic; moderate impact.
- A127P (p.Ala127Pro), TOPMed rs2065763765, gnomAD rs2065763765, REVEL 0.16, CADD 4.54
- E128K (p.Glu128Lys), NCI-TCGA TCGA novel, REVEL 0.02, CADD 4.49, Variant assessed as somatic; moderate impact.
- A129S (p.Ala129Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- W130C (p.Trp130Cys), rs2521947003, ClinGen CA415153591, ClinVar RCV003966875, Uncertain significance, IRAK1-related disorder
- W130* (p.Trp130Ter), gnomAD X-154011907-C-T, CADD 14.10, SIFT 0.00
- W130S (p.Trp130Ser), gnomAD X-154011907-C-G, CADD 8.14, SIFT 0.39
- S131N (p.Ser131Asn), gnomAD rs1557130710, REVEL 0.05, CADD 1.28
- P132L (p.Pro132Leu), rs2148643448, ClinGen CA415153528, ClinVar RCV004314310, Ensembl rs2148643448, AlphaMissense 0.08, MetaLR 0.28, Uncertain significance, not specified
- R133G (p.Arg133Gly), TOPMed rs1303739665, gnomAD rs1303739665, REVEL 0.07, CADD 15.20
- R133Q (p.Arg133Gln), ExAC rs782265613, TOPMed rs782265613, gnomAD rs782265613, REVEL 0.06, CADD 9.56, Uncertain significance, not specified
- R133K (p.Arg133Lys), gnomAD X-154011901-C-T, CADD 2.37, SIFT 0.24
- R133H (p.Arg133His), rs782759071, gnomAD X-154012545-C-T, CADD 0.35, SIFT 0.15
- P136L (p.Pro136Leu), ExAC rs782689273, gnomAD rs782689273, REVEL 0.12, CADD 1.91
- P136R (p.Pro136Arg), ExAC rs782689273, gnomAD rs782689273, REVEL 0.11, CADD 2.51, Uncertain significance, not specified
- P136S (p.Pro136Ser), TOPMed rs1367337913, gnomAD rs1367337913, REVEL 0.10, CADD 14.20
- A139V (p.Ala139Val), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- S140F (p.Ser140Phe), gnomAD rs906604012, REVEL 0.13, CADD 24.00
- T141P (p.Thr141Pro), rs994323796, ClinGen CA337256690, ClinVar RCV004258670, gnomAD rs994323796, REVEL 0.19, CADD 24.50, Uncertain significance, not specified
- P145S (p.Pro145Ser), TOPMed rs2065763140, REVEL 0.19, CADD 23.70
- P145R (p.Pro145Arg), gnomAD X-154012536-G-C, CADD 0.51, SIFT 0.06
- P145L (p.Pro145Leu), rs2065706971, gnomAD X-154012536-G-A, CADD 0.63, SIFT 1.00
- A146V (p.Ala146Val), ExAC rs782013472, gnomAD rs782013472, REVEL 0.15, CADD 20.80
- F147L (p.Phe147Leu), gnomAD X-154011854-A-G, CADD 3.05, SIFT 0.26
- P148L (p.Pro148Leu), rs375736059, NCI-TCGA Cosmic COSV5765, cosmic curated COSV57653, ESP rs375736059, REVEL 0.23, CADD 24.90, Uncertain significance, not specified
- P148S (p.Pro148Ser), cosmic curated COSV10514, gnomAD rs1557130583, REVEL 0.16, CADD 18.20
- S150C (p.Ser150Cys), Ensembl rs2065761985, REVEL 0.20, CADD 18.90
- T152S (p.Thr152Ser), rs782422452, ClinGen CA10558334, ClinVar RCV004244419, ExAC rs782422452, REVEL 0.05, CADD 6.56, Uncertain significance, not specified
- S154* (p.Ser154Ter), Ensembl rs1603304937
- G155D (p.Gly155Asp), rs1452696311, gnomAD X-154011889-C-T, CADD 7.50, SIFT 0.01
- P156R (p.Pro156Arg), NCI-TCGA Cosmic COSV1003, cosmic curated COSV10031, Variant assessed as somatic; moderate impact.
- P156L (p.Pro156Leu), rs139615756, gnomAD X-154011886-G-A, CADD 2.17, SIFT 1.00
- P156Q (p.Pro156Gln), gnomAD X-154011886-G-T, CADD 1.86, SIFT 0.27
- L158H (p.Leu158His), 1000Genomes rs782766861, ExAC rs782766861, gnomAD rs782766861, REVEL 0.21, CADD 15.40
- L158R (p.Leu158Arg), 1000Genomes rs782766861, ExAC rs782766861, gnomAD rs782766861
- G159A (p.Gly159Ala), ExAC rs782338967, TOPMed rs782338967, gnomAD rs782338967, Uncertain significance
- G159D (p.Gly159Asp), rs782338967, ClinGen CA10558331, ClinVar RCV004256847, ExAC rs782338967, REVEL 0.21, CADD 6.67, Uncertain significance, not specified
- G159S (p.Gly159Ser), ExAC rs781996777, TOPMed rs781996777, gnomAD rs781996777, REVEL 0.13, CADD 2.75
- V161M (p.Val161Met), gnomAD X-154011857-C-T, CADD 0.09, SIFT 0.15
- P162S (p.Pro162Ser), cosmic curated COSV57658, ExAC rs781937652, TOPMed rs781937652, gnomAD rs781937652, REVEL 0.14, CADD 13.40, Uncertain significance, not specified
- P164L (p.Pro164Leu), 1000Genomes rs781895342, REVEL 0.11, CADD 14.00
- P164S (p.Pro164Ser), TOPMed rs2065761503, gnomAD rs2065761503, REVEL 0.10, CADD 9.31
- A165V (p.Ala165Val), rs782295969, ClinGen CA10558327, ClinVar RCV004294356, ExAC rs782295969, REVEL 0.11, CADD 13.80, Uncertain significance, not specified
- A165G (p.Ala165Gly), rs1557127575, gnomAD X-154011844-G-C, CADD 12.00, SIFT 0.39
- A165T (p.Ala165Thr), gnomAD X-154011845-C-T, CADD 9.35, SIFT 0.19
- W168C (p.Trp168Cys), gnomAD X-154011846-C-G, CADD 10.30, SIFT 0.02
- W168R (p.Trp168Arg), gnomAD X-154011848-A-G, CADD 2.29, SIFT 0.04
- P169A (p.Pro169Ala), NCI-TCGA Cosmic COSV1003, cosmic curated COSV10031, Variant assessed as somatic; moderate impact.
- P170S (p.Pro170Ser), NCI-TCGA TCGA novel, CADD 6.96, Variant assessed as somatic; moderate impact.
- P170P (p.Pro170Pro), gnomAD X-154011837-G-C, CADD 9.93
- P170L (p.Pro170Leu), rs1168861199, gnomAD X-154011838-G-A, CADD 12.80, SIFT 0.11
- P170T (p.Pro170Thr), gnomAD X-154011839-G-T, CADD 6.46, SIFT 0.33
- P170A (p.Pro170Ala), rs781995118, gnomAD X-154011839-G-C, CADD 6.59, SIFT 0.87
- P171L (p.Pro171Leu), TOPMed rs1206351667, gnomAD rs1206351667, REVEL 0.07, CADD 0.17
- P171S (p.Pro171Ser), gnomAD rs1557130559, CADD 8.33
- P171Q (p.Pro171Gln), gnomAD X-154011834-TG-T, CADD 7.17
- P171T (p.Pro171Thr), gnomAD X-154011836-G-T, CADD 7.87, SIFT 0.23
- P172L (p.Pro172Leu), TOPMed rs936051251, gnomAD rs936051251, REVEL 0.11, CADD 9.00, Uncertain significance, not specified
- P172S (p.Pro172Ser), gnomAD rs1557130554
- S173F (p.Ser173Phe), TOPMed rs2065761240
- P174L (p.Pro174Leu), NCI-TCGA TCGA novel, REVEL 0.08, CADD 16.50, Uncertain significance, not specified
- P174S (p.Pro174Ser), gnomAD rs1557130542, REVEL 0.04, CADD 9.54
- A175D (p.Ala175Asp), rs2521945482, ClinGen CA415152051, ClinVar RCV004180847, Uncertain significance, not specified
- P176A (p.Pro176Ala), ExAC rs782643146, gnomAD rs782643146, REVEL 0.09, CADD 16.40
- P176L (p.Pro176Leu), TOPMed rs1460615442, REVEL 0.11, CADD 17.90
- S177F (p.Ser177Phe), rs202066173, ClinGen CA10558325, ClinVar RCV003440028, ClinVar RCV005854500, REVEL 0.09, CADD 22.80, Conflicting interpretations, not provided; not specified
- S178A (p.Ser178Ala), TOPMed rs1244752648, gnomAD rs1244752648, REVEL 0.07, CADD 15.10
- T179S (p.Thr179Ser), TOPMed rs2065760938
- T179T (p.Thr179Thr), gnomAD X-154011090-G-T, CADD 0.71
- T179N (p.Thr179Asn), gnomAD X-154011091-G-T, CADD 2.77, SIFT 0.06
- T179I (p.Thr179Ile), rs1325815677, gnomAD X-154011091-G-A, CADD 3.32, SIFT 0.02
- K180Q (p.Lys180Gln), rs782216618, ClinGen CA10558324, cosmic curated COSV57655, ClinVar RCV004403184, REVEL 0.04, CADD 15.30, Uncertain significance, not specified
- K180R (p.Lys180Arg), gnomAD rs1557130517, REVEL 0.07, CADD 22.80
- K180V (p.Lys180Val), rs1557127286, gnomAD X-154011063-CTT-C, CADD 0.80
- K180N (p.Lys180Asn), gnomAD X-154011081-T-G, CADD 5.13, SIFT 0.05
- K180E (p.Lys180Glu), rs1387376337, gnomAD X-154011101-T-C, CADD 5.43, SIFT 0.02
- K180T (p.Lys180Thr), rs782169186, gnomAD X-154011820-T-G, CADD 11.70, SIFT 0.17
- P181R (p.Pro181Arg), gnomAD rs1557130442, REVEL 0.10, CADD 1.29
- P181L (p.Pro181Leu), rs1557127304, gnomAD X-154011109-G-A, CADD 2.38, SIFT 0.01
- P181H (p.Pro181His), gnomAD X-154011109-G-T, CADD 1.94, SIFT 0.00
- P181T (p.Pro181Thr), gnomAD X-154011110-G-T, CADD 1.18, SIFT 0.01
- G182D (p.Gly182Asp), rs970495832, Ensembl rs970495832, REVEL 0.08, CADD 2.38, Variant assessed as somatic; moderate impact.
- P183R (p.Pro183Arg), 1000Genomes rs782031474, ExAC rs782031474, TOPMed rs782031474, gnomAD rs782031474, REVEL 0.17, CADD 11.40
- E184G (p.Glu184Gly), TOPMed rs2065758939, REVEL 0.08, CADD 11.50
Public IRAK1 analysis runs
- IRAK1 analysis run — IRAK1 (840 variants) — completed 2026-08-20